Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke — CLEVER  

Blood Pressure Clinical Trial

Official title: Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke (CLEVER)

Status Recruiting

Clinical Trial Summary

The CLEVER Study is a prospective, 2-arm, randomized, single-center pilot study to assess the safety and efficacy of intensive blood pressure control using Clevidipine (on-label use) in AIS patients undergoing standard of care mechanical thrombectomy (MT) within 24-hours of symptoms onset.

Clinical Trial Description

The CLEVER Study is a prospective, 2-arm, randomized, single-center pilot study to assess the safety and efficacy of intensive blood pressure control using Clevidipine (on-label use) in AIS patients undergoing standard of care mechanical thrombectomy (MT) within 24-hours of symptoms onset. Eligible patients will be randomized 1:1 to a systolic blood pressure goal after successful MT (mTICI 2c or greater) of either: 90-120mmHg (Intensive BP management group) or 90-160mmHg (Standard BP management group). Patients enrolled into the study will be followed and assessed for up to 3 months. ;

Related Conditions & MeSH terms

• Blood Pressure
• Ischemic Stroke
• Mechanical Thrombectomy
• Stroke
• Stroke, Acute

• NCT number: NCT05175547
• Study type: Interventional
• Source: ProMedica Health System
• Contact: Mouhammad Jumaa, MD
• Phone: 419-291-8027
• Email: Mouhammad.JumaaMD@ProMedica.org
• Status: Recruiting
• Phase: Phase 3
• Start date: November 1, 2021
• Completion date: November 1, 2025